In order to determine the initial values and dynamic changes of EPO (erythropoietin) after therapy, 57 consecutively presenting, typical COPD (chronic obstructive pulmonary disease) patients with chronic hypoxia and acute exacerbated serum EPO levels were serially measured. Initial mean EPO levels were slightly above the normal range (41.4 + − 83.5 units/l), but in the majority of patients the initial EPO levels were significantly reduced. Following the correction of hypoxaemia, mean EPO levels decreased to 14.1 + − 16.9 units/l (P = 0.0093). However, not all COPD patients showed this pattern; in an important subset of patients (36.8 %), who had initially lower EPO levels and lower erythrocyte count, EPO levels were significantly increased (by more than 60 %; P = 0.0028) on the second day of treatment, despite correction of the hypoxaemia. This finding was unexpected and paradoxical when compared with physiological studies addressing the same issue. The data presented support previous reports of variable EPO levels in severely hypoxic COPD patients and suggest that the haematological response is already hampered at an early stage, at the level of EPO production, and much less likely at later steps in the haemopoietic response by failure to respond to elevated EPO levels. Our data are consistent with recent discoveries that the O 2 sensing and regulation of EPO production is a complex process in which multiple factors, including cytokines and therapeutic agents, play a role by enhancing or inhibiting the response. We believe that further studies on this clinical condition are complementary to basic physiological research and may help to elucidate the role of cytokines and other individual factors in complex clinical hypoxic situations.
INTRODUCTION
The erythrocyte mass has the primary function of transporting O 2 to the tissues [1] . EPO (erythropoietin) is a physiological regulator of erythrocyte production. EPO maintains erythrocyte production by inhibiting apoptosis of erythrocytic progenitors and by stimulating their proliferation and differentiation into normoblasts [2] . The fundamental stimulus for EPO production is the availability of O 2 for tissue metabolic needs. Impaired O 2 delivery to the kidney can result from a decreased erythrocyte mass (anaemia), impaired O 2 loading of the haemoglobin molecule (hypoxaemia) or impaired blood flow to the kidney (renal artery stenosis). Elevated EPO production results in an increased erythroid cell production in haematopoietic tissues. This results in an increase in the O 2 -carrying capacity of the blood, thereby alleviating the hypoxic stimulus and providing a negative feedback loop shutting off EPO production [3] . The relationship between erythrocyte mass and awake O 2 saturation is linear in healthy human subjects [4] .
For the last decade, EPO regulation and O 2 sensing has been intensively investigated in experimental models, which led to the recognition of complex signalling transduction pathways. Thus activation of transcription of the EPO gene is mediated by HIF (hypoxiainducible factor)-1 [5, 6] . Expression of HIF-1 increases exponentially as cellular O 2 concentration decreases [7] . Experiments indicate that the activation of HIF-1 involves redox-dependent stabilization of HIF-1α protein [8] . An active heterodimeric HIF transcription factor binds to the enhancer and stimulates EPO gene transcription [6] . Two separate domains within HIF-1α are responsible for the mechanism by which cellular O 2 regulates HIF-1 activity. The O 2 -dependent degradation domain was discovered first; in normoxia it is hydroxylated by specific prolyl hydroxylases (PHD1, PHD2, and PHD3) [9, 10] . pVHL (Von Hippel-Lindau tumour suppressor protein) binds to the hydroxylated form of HIF-1α and mediates its ubiquitination and proteosomal degradation [11] . A second hypoxic switch has recently been identified [12] to operate in the Cterminal activation domain, where a conserved asparagine residue is hydroxylated by FIH-1 (factor inhibiting HIF-1), which results in a decreased ability of HIF-1 to bind to the transcriptional coactivator. It is proposed that PHDs and FIH-1 serve as O 2 sensors in the hypoxia pathway [13] .
However, a number of controversies have arisen with respect to the precise action of individual factor(s) in defined conditions, especially in complex clinical situations in which more than one factor in addition to hypoxia (including cytokines, drugs etc.) may be operating. We have studied a clinical model of COPD (chronic obstructive pulmonary disease) accompanied by severe hypoxaemia due to acute exacerbation that required hospitalization. Although COPD is regularly reported as a cause of secondary polycythaemia [3, 14] , only a minor subset of these patients who are chronically hypoxaemic develop secondary erythrocytosis [15] . The measurement of EPO levels in vivo in this subset of patients gave discordant results and considerable variations occurred from patient to patient [15] [16] [17] .
The aim of this prospective intervention study was to evaluate haematological parameters and EPO levels in patients with acute exacerbation of chronic hypoxic lung disease and to evaluate their response to correction of hypoxia.
METHODS

Selection of patients
Fifty-seven consecutive patients with COPD in acute exacerbation of chronic respiratory failure for various reasons and severe hypoxaemia with Pao 2 (partial arterial O 2 pressure) 53 mmHg entered the study. None of the patients was receiving continuous O 2 therapy before admission to the hospital. Patients had no significant renal or liver dysfunction nor had clinical signs of gastrointestinal bleeding. The diagnosis of COPD was established by clinical, radiological and laboratory tests in line with guidelines recommended by the American Thoracic Society [18] . Over 90 % of patients were admitted during the morning hours. The onset of acute exacerbation was clinically assessed to be at least 24 h prior to hospitalization in all patients studied. The Institutional Ethical Committee approved the study and informed consent was obtained from all participants.
Treatment
Treatment was promptly instituted according to good clinical practice, including O 2 , β 2 -agonists, anticholinergics, theophylline, corticosteroids, diuretics, hypotensive drugs and antibiotics, as clinically appropriate. O 2 was prescribed 24 h/day and was delivered via a nasal cannula at 4 litres/min to correct hypoxaemia. In a few patients who retained CO 2 and were mainly mouth breathers or had extreme nasal irritation, Venturi masks were used. The goal of O 2 therapy was to correct hypoxaemia to Pao 2 > 60 mmHg or SatHbo 2 (haemoglobin O 2 saturation) > 90 %.
Laboratory analyses
The following blood samples were taken during the study: at the moment of admission to the hospital (sample 1), the next day (sample 2), at day 8 (sample 3), at day 14 (sample 4), and more frequently when clinically indicated.
Blood samples for the determination of Pao 2 , Paco 2 (partial arterial CO 2 pressure), SatHbo 2 and pH were drawn anaerobically from the radial artery into heparinized plastic syringes and routine haematological and biochemical analyses were performed by standard biochemical methods. The serum samples for the determination of EPO were frozen within 1 h of collection at the temperature of − 40
• C. All samples were analysed after the study period at the same time. EPO was measured using a commercially available ELISA. With this assay, the reference range of normal values of serum EPO in adults was between 4.3-32.9 units/l (Sangui Bio Tech Inc., Santa Ana, CA, U.S.A.).
Statistical analysis
Results were statistically analysed with parametric and non-parametric tests as appropriate, by using Statview 
RESULTS
Baseline findings
Characteristics of patients who fulfilled the entry criteria are shown in detail in Tables 1 and 2, with Table 1 providing demographical and clinical information and Table 2 the respiratory, haematological and biochemical parameters. Continuous data are presented as arithmetic means + − S.D., and nominal data are presented as a proportion of the whole population. To assess the difference between genders with respect to continuous data, Student's t tests were used, and to assess the difference between genders regarding nominal data χ 2 tests were used. It can be seen that all the patients have clinical characteristics of COPD, which included chronic cough, sputum production and dyspnoea. In all patients, acute exacerbation lasted more than 24 h prior to admission. The cause of exacerbation was bronchopulmonary infection in ten patients, congestive heart failure in 21 patients, and a combination of the two conditions in 26 patients. Incidence of global heart failure as well as isolated left and right heart failure are shown separately. Incidence of previously known hypertension, hypertension observed at admission and mean arterial pressure measured at admission into the hospital is also presented. Table 1 also provides information regarding therapy used immediately before hospitalization and therapy instituted in the hospital. Attention was paid to the most important groups of medications used in treating COPD: β 2 -agonists, anticholinergics, methylxanthines (aminophylline and theophylline), glucocorticosteroids, diuretics and antibiotics. All parameters were evenly distributed between genders, except for global heart failure, which was more frequently observed in women, and anticholinergics, which were more frequently used in men during hospitalization. As shown in Table 2 , the haematological and biochemical parameters as well as the results of arterial blood gas analyses were evenly distributed between genders. According to entry criteria, all patients were severely hypoxic at the time of admission while breathing air. Mean Paco 2 tension values were slightly above normal ranges, which is typical for this patient population. Mean haemoglobin values were within reference range. In 32 out of 57 patients (14 male and 18 female), haemoglobin was normal, ten out of 57 patients (seven male and three female) were anaemic, and 15 out of 57 (five male and ten female) were polycythaemic.
Average values of urea and creatinine, as parameters of renal function, were within the reference range. Urea was above the reference range in 11 out of 57 patients (six men and five women) with a maximum value of 16.2 mmol/l (less then twice the upper normal limit). Creatinine was found above reference range in eight out of 57 patients (five men and three women) with a maximum value of 142.0 µmol/l (less then once the upper normal limit).
The mean pH value was at the upper level of the reference range. It was within the normal range in 31 out of 57 patients. Acidosis was found in two out of 57 patients (one man and one woman) with a minimum value of 7.3, whereas alkalosis was found in 24 out of 57 patients (ten men and 14 women) with a maximum value of 7.64.
The distribution of initial EPO values was significantly different from a normal distribution (KolmogorovSmirnov test: d = 0.408; P < 0.01; Figure 1) , and fitted better with a log-normal distribution. Initial EPO levels were within the reference range in 38 out of 57 patients, were decreased in ten out of 57, and were increased in only nine out of 57 patients. In seven out of 57 patients, the EPO levels were very high (above 100 units/l). These nine patients with elevated EPO levels were responsible for the increased mean EPO being significantly different from median and geometric mean values. For this reason, log-transformation was used for all parametric statistical analyses. After the transformation the Kolmogorov-Smirnov test showed d = 0.130 (P = not significant). Mean initial EPO levels were above the reference range and were 41.4 + − 83.5 units/l. Median EPO values were 11.0 units/l, indicating that in the majority of patients EPO levels were low. We performed an extensive analysis of possible associations of initial log-EPO variable and other variables stipulated in Tables 1 and  2 . A statistically significant negative correlation between initial log-EPO levels and initial Pao 2 (R = − 0.376, P = 0.0043) was found. A statistically significant positive correlation was found between the initial EPO values and initial alanine aminotransferase (R = + 0.306, P = 0.0229), urea (R = + 0.407, P = 0.0020), creatinine (R = + 0.294, P = 0.0294) and potassium (R = + 0.340, P = 0.0118) values. No significant correlation was found between initial EPO values and therapy used at home.
Changes induced by treatment
We analysed further changes induced by treatment primarily of O 2 , but also by addition of other drugs. Correction of O 2 was associated with a moderate increase of Paco 2 tension as shown in Figure 2(B) . Over the same 2-week interval, a statistically significant decrease in erythrocyte parameters were observed (Figure 2C) . A decrease of 3.9 % in haemoglobin was observed from day 1 to day 2 and 9.7 % from day 1 to day 14. Using the paired Student's t test, this observation was found to be statistically significant regarding both intervals (P < 0.0001). When the entire patient group was analysed (with caution because the parameter was not normally distributed), the mean initial EPO level was 41.4 + − 83.5 units/l and this significantly decreased (to 14.1 + − 16.9 units/l) within the first 24 h of follow-up (P = 0.0093). However, more detailed analyses of individual patients showed that EPO did not show a unique pattern in all the patients (Figure 3) . In 36 out of 57 patients (17 male and 19 female), a fall in EPO levels was observed within 24 h, but in 21 out of 57 (nine male and 12 female), EPO rose over the same time interval. Thus we identified two groups of different responders to hypoxaemia correction: (A) a larger subset (63.2 %) with the expected response, i.e. a decrease in EPO levels after correction of hypoxaemia, and (B) a smaller subset (36.8 %) with an unexpected response, i.e. an increase of EPO levels after correction of hypoxaemia. The mean changes in EPO levels were statistically significant in both patient subsets, although in the opposite direction ( Figure 3) .
All available parameters were compared between these two patient subsets to identify factors possibly responsible for the decrease or increase of EPO levels after correction of hypoxaemia. A significant difference was found only for initial log-EPO (P = 0.0015) and initial erythrocyte (P = 0.0278) levels and the use of angiotensin-converting-enzyme (ACE) inhibitors in hospital (P = 0.0341). The initial EPO and erythrocyte levels were lower in subset B, and the proportion of patients in whom ACE inhibitors were used was smaller in subset B than in subset A. No other significant differences were observed with respect to all other clinical (including medication), respiratory, biochemical and haematological parameters studied at admission.
We analysed in detail the impact of hospital-instituted therapy on changes of EPO levels. After admission, in addition to O 2 , more therapy was administered upon hospitalization, as shown in Table 1 . We did not find any correlation with EPO dynamics for any other drug used, except ACE inhibitors.
DISCUSSION
The present study has shown that, in severely hypoxic COPD patients, initial EPO levels are significantly impaired in the majority of patients, despite a slightly increased mean initial EPO level for the whole studied population. This reflects a log-normal distribution of initial EPO levels. The impaired EPO level is probably due to an underlying disturbance in the O 2 -sensing mechanism(s) and/or of EPO gene activation. Concordantly, polycythaemia was found only in a minority of patients. We describe an unusual, paradoxical and significant EPO increase after correction of hypoxaemia in a subset (36.8 %) of patients. This was found more frequently in patients who initially had lower EPO and erythrocyte levels.
The present study was carried out on a group of consecutive COPD patients admitted to hospital with acute exacerbation associated with severe respiratory failure lasting more than 24 h. All of them were severely hypoxic breathing air, with Pao 2 53 mmHg. Because severe and prolonged hypoxaemia is known as the strongest physiological stimulus for EPO production [1, 3] , these patients were used as a model to evaluate the hypoxia-induced haematological response. Since COPD is a common clinical condition in which the causes of acute exacerbation may vary and since there may be co-morbidity which requires different chronic therapy and therapy modification in addition to O 2 therapy on admission, we have described the clinical and laboratory data available in detail and have performed extensive analyses to assess their impact on the hypoxia/ EPO/haemopoiesis relationship. This clinical study population is clearly distinct from physiological models that address the same question and, therefore, offers an interesting model for studying EPO production in complex clinical situations.
The relationship between erythrocyte mass and awake O 2 saturation is linear in healthy human subjects [4] . It is, however, well known that in patients with COPD the haematocrit may be normal, reduced or increased [14, 18] . The same finding was seen in our present study. The mean haemoglobin concentration in our study population was within the normal reference range. More detailed analysis showed that, despite severe hypoxaemia, most of our patients had normal or subnormal haemoglobin values, and only 15 (26 %) of our patients had polycythaemia. In this, as well as in all other respects, our study population was typically representative of COPD with severe hypoxia.
The difference between physiological models used to study hypoxia-induced haematological response and COPD patients with severe hypoxia has been attributed to iron deficiency, increased carboxyhaemoglobin levels, nocturnal-or exercise-induced desaturation or bone marrow suppression due to severe hypoxia or chronic inflammation associated by the action of various activated cytokines [17, [19] [20] [21] [22] . In particular, it has been reported [23] that acidosis inhibits hypoxia-induced triggering of EPO production independently of CO 2 and bicarbonate levels. On the other hand, Vlahakos et al. [24] suggested that activation of the renin-angiotensin system is a potential mediator of secondary erythrocytosis in chronically hypoxaemic patients with COPD.
The potential influence of many drugs on serum EPO levels has been investigated. Fenoterol, a selective β 2 -adrenoceptor agonist, increases EPO concentration, although this same effect is not associated with the inhalation of high doses of salbutamol [25, 26] . It has also been reported [27] that glucocorticoids can influence fetal renal (but not maternal) EPO gene expression in experimental animals, but their therapeutic value and the impact on EPO synthesis is still unclear. For example, it is known that dexamethasone may cause a reduction in the secretion of EPO-inhibitory cytokines from monocytes [28] . However, in children with acute leukaemia and in patients with rheumatoid arthritis, corticosteroid treatment may improve haemoglobin levels without changing EPO activity [29] . Furthermore, several groups [30, 31] have reported that ACE inhibitors may decrease serum EPO levels. In summary, these reports provide no obvious unifying explanation for the observed difference between physiological models of hypoxia and COPD patients or among COPD patients.
Considering serum EPO levels, previous studies have shown that in stable COPD patients with sustained chronic hypoxia, EPO levels are variable: they were normal or increased with significant variability among patients [15] [16] [17] . It has also been reported [32] that patients with stable COPD are able to produce a rise in serum EPO as early as 2 h following the onset of an acute hypoxaemic stress. In the present study, the correction of hypoxia was accompanied by a steady decrease in haematocrit values as early as 24 h and continued until 14 days after the beginning treatment. O 2 therapy in COPD patients can reverse secondary polycythaemia [33] , and the correction of hypoxaemia in stable COPD patients is accompanied by a decrease of EPO levels [15] . It is, however, highly unlikely that such changes in EPO levels can result in such a prompt change in haematocrit, since erythrocyte life span is 120 days and erythropoiesis does not immediately cease when EPO levels fall: a change in erythrocyte synthesis would take approx. 14 days to be manifested.
Plasma volume was not determined in our present study group, but it is unlikely that a decrease in haemoglobin levels can be explained by treatment. Moreover, the decrease in haematocrit observed was far too large to be explained merely by the blood loss caused by sample drawing for analysis.
It is hard to explain the relatively low EPO levels at baseline in the whole study group. Indeed, it is obvious that chronic hypoxia failed to induce an increase in EPO levels in the majority of our patients. We performed extensive analysis of the potential influences of different therapies used immediately before hospitalization on EPO levels, but we did not find any statistically significant correlation.
The further surprising finding of our present study, which has not been reported previously, was that in 36.8 % of patients the EPO level increased on the second day of treatment, despite the correction of hypoxaemia. In this subset (subset B) of patients, the initial EPO and erythrocyte levels were lower, and the proportion of patients in whom ACE inhibitors were used was smaller in subset B than in A. The latter finding suggests that ACE inhibitors could contribute to a decrease in EPO levels during hospitalization. This observation is consistent with other reports [30, 31] , which were made on different experimental models, showing that ACE inhibitors can decrease EPO levels. The rise of EPO on the second day of treatment may indicate that EPO production is initially inhibited by some factors that can be promptly changed, such as proinflammatory cytokines. COPD is characterized by increased cytokine levels in sputum as well as in serum [22, 34] .
It is becoming increasingly clear that HIF-1 plays a major role in hypoxic signalling pathway(s) for EPO. Although HIF-1 is regulated mainly by O 2 tension through the O 2 -dependent degradation of its α subunit, there is evidence [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] in vitro and in some clinical conditions that HIF can also be modulated by cytokines, hormones and genetic alterations. Thus experimental data show that TNF-α (tumour necrosis factor-α), derived from activated macrophages, can provoke HIF-1α stabilization in cells under normoxic conditions [35, 36] . Also IL-1β (interleukin-1β) and TNF-α stimulate DNA binding of HIF-1 [37] . However, chronic inflammatory disease, which is often related to COPD, is associated with normocytic and normochromic anaemia, which is partly caused by a lack of EPO [38, 39] . Moreover, recent studies [40] suggest that IL-1 and TNF-α suppress in vitro EPO gene expression and EPO protein secretion by activation of GATA-2 and NF-κB (nuclear factor κB) transcription factors. Furthermore, some in vivo experiments have suggested that anaemia of chronic disorders is not characterized by inadequate EPO production, but that cytokines probably act directly on bone marrow erythrocyte precursors [41] . In vivo experiments also suggest that TNF-α can exert a suppressive effect on EPO secretion in patients with advanced solid tumours, leukaemia and chronic infection [42] [43] [44] . In addition, the plasma level of EPO in anaemic patients suffering from severe inflammation is often low in relation to the blood haemoglobin concentration [45] . Therefore it seems likely that EPO production is increased in some of the patients in the present study as a result of a reduction in inflammation, although we failed to find a statistically significant association between clinical findings of infection and EPO dynamics.
It is obvious that the disturbance in the signalling cascade we have observed in COPD patients may be at the levels of O 2 sensing, gene transcription or activation of erythroid progenitors in bone marrow. Our present results showing low EPO levels, despite severe hypoxaemia, indicate that an inadequate erythropoietic reaction to hypoxia is predominantly hampered at the level of EPO production due to failure of the O 2 -sensing mechanism and/or EPO gene activation. It is less likely that an enhanced EPO degradation or erythroid clearance at the level of bone marrow results in the decreased EPO levels. This present study shows that the erythropoietic response failure at the level of bone marrow is the least likely possibility. We believe that further studies in this clinical condition of COPD are complementary to basic physiological research and may help to elucidate the role of drugs and cytokines in complex clinical hypoxic situations.
